Individualizing PAH Therapy in an Evolving Treatment Landscape - Episode 11
PAH Medication Side Effects: Tolerability, Titration, and Shared Decision-Making
Side effects overlap with disease symptoms and vary widely between patients. The panel outlines how education, careful titration, patient portals, and dedicated nurses and pharmacists help patients stay on therapy.
The panel's discussion in "PAH Medication Side Effects: Tolerability, Titration, and Shared Decision-Making" centers on the safety questions that shape shared decision-making.
Dr. McLaughlin asks the panel to summarize safety and side effects as part of shared decision-making. Dr. Channick notes that many drugs share similar side effects and that some overlap with disease symptoms. Edema with endothelin receptor antagonists can be severe, yet it may also signal worsening right ventricular function. Other common effects include headache, reflux, and a range of gastrointestinal symptoms, while newer therapies add distinct effects such as rashes, nosebleeds, oral bleeding, and changes in hemoglobin. There have also been reports of intrapulmonary shunting, so the picture includes known and unknown concerns.
Tolerability varies widely. Some patients notice nothing, while others have many effects at low doses and need very gentle titration, and prostacyclin pathway drugs must be advanced neither too quickly nor too slowly. Clinicians review every side effect up front, but patients cannot grasp the experience until they live it and may simply want to stop.
Support from the team helps. Dr. Channick finds the electronic record patient portal valuable, because patients can send messages instead of leaving voicemails and the team can monitor tolerability closely. Dr. Vaidya says any lifeline to the program, whether a portal or a direct phone number, provides reassurance that a side effect is not dangerous and that the team can help treat through it. Dr. Kim values having a pharmacist on staff alongside the nurses.
Asked for an example of side effects changing a decision, Dr. Kim cites a young heritable PAH patient who feels well and does not want to discuss parenteral therapy. Such patients need time and education, and some arrive with inaccurate claims from the internet. Patients who know about side effects handle them better, and Dr. McLaughlin adds that the team has tools to manage vasodilatory effects of parenteral prostacyclins and cough.
Up next, in "PAH Treatment Adherence and Quality of Life: Reducing Pill Burden," Dr. Vaidya leads a discussion on why patients stop therapy and how quality of life fits in.
